We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests

By LabMedica International staff writers
Posted on 16 Jul 2025

QuidelOrtho Corporation (San Diego, CA, USA) and BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) have announced the availability of the BÜHLMANN

labmedica.com/expo/product/18767/rapid-calprotectin-test-model-b-hlmann-fcal-turbo" target="_blank">fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.

This collaboration addresses key healthcare trends, including the rise of non-invasive diagnostic tools, the demand for cost-effective healthcare solutions, and the growing focus on gastrointestinal and pancreatic health and its systemic impact. The fCAL and fPELA turbo assays exemplify innovation in diagnostics technology, supporting the shift toward tailored medicine and preventive healthcare. The fCAL and fPELA turbo assays are both now available for use on QuidelOrtho's VITROS Systems: VITROS XT 7600 and 5600 Integrated System, as well as VITROS 4600 Chemistry Systems.

These assays contribute to better management of gastrointestinal health, reducing the need for invasive procedures and lowering long-term healthcare costs. Both assays utilize BÜHLMANN's innovative CALEX Cap technology, which simplifies sample extraction and preparation while facilitating safe handling – all seamlessly integrated onto a single VITROS System. The fCAL and fPELA turbo assays' integration with VITROS Systems offers laboratories an efficient workflow for a wide variety of sample collection methods, enhancing flexibility in sample handling and processing.

"The integration of BÜHLMANN's fCAL and fPELA turbo assays with our VITROS Systems represents a significant advancement in IBD and pancreatic insufficiency diagnoses," said Jonathan Siegrist, PhD, Executive Vice President of Research & Development & Chief Technology Officer at QuidelOrtho. "This collaboration allows laboratories to provide fast results to aid in the diagnosis and management of IBD and pancreatic issues, ultimately improving patient care."

"We are thrilled to collaborate with QuidelOrtho to expand the delivery of an efficient, automated solution for fecal biomarker testing," added Christian Eberle, Chief Executive Officer at BÜHLMANN Laboratories AG. "Our assays, combined with the CALEX Cap stool preparation device, optimize stool extraction efficiency to help maximize stability and yield, resulting in robust fecal calprotectin and pancreatic elastase test results. This collaboration between QuidelOrtho and BÜHLMANN Laboratories AG meets evolving patient and provider needs in the era of personalized medicine and preventive healthcare, offering innovative solutions that align with the industry's focus on non-invasive, cost-effective, and patient-centric diagnostic tools."

Related Links:
QuidelOrtho
BÜHLMANN Laboratories


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Genai-based pathological assessment workflow for lung adenocarcinoma (Shen J. et al., Int J Surg 111(7): 4252–4262; 2025)

Generative AI Demonstrates Expert-Level Pathological Assessment of Lung Cancer

Lung adenocarcinoma is one of the most difficult cancers to diagnose accurately, requiring pathologists to spend extensive time examining tissue samples under microscopes to determine tumor grades and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.